Lexeo Therapeutics, Inc.
LXEO
$5.09
-$0.41-7.46%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 19.95% | -1.66% | -21.21% | -47.86% | -57.46% |
| Total Depreciation and Amortization | 4.79% | 3.85% | 4.62% | 6.19% | 8.28% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -43.31% | -29.03% | -4.09% | 44.88% | 151.12% |
| Change in Net Operating Assets | -475.20% | -448.66% | -273.59% | 28.35% | -9.92% |
| Cash from Operations | -11.35% | -21.45% | -59.88% | -51.02% | -57.17% |
| Capital Expenditure | -45.95% | 17.46% | 28.34% | 59.70% | 1.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.04% | 4.00% | -628,738.46% | -185,692.06% | -134,362.07% |
| Cash from Investing | -0.14% | 4.07% | -14,387.83% | -21,732.40% | -21,767.04% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -7.61% | -30.00% | -20.30% | -28.61% | -8.49% |
| Issuance of Common Stock | 3,329.11% | 145.13% | -58.96% | -59.00% | -96.35% |
| Repurchase of Common Stock | -- | -- | 69.23% | 69.23% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -166.82% | -166.42% | -8.72% | -8.54% | -7,210.47% |
| Cash from Financing | 164,739.10% | 144.20% | -61.40% | -62.26% | -99.93% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 125.79% | 132.37% | -195.44% | -207.77% | -221.99% |